We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
Coverage of stories discussed this week on ascopost.com:
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
Coverage of stories discussed this week on ascopost.com:
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
Coverage of stories discussed this week on ascopost.com:
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
Coverage of stories discussed this week on ascopost.com:
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma